Why the study?
The mechanistic role of apoptosis-stimulating protein p53 2 (ASPP2) in the development of metabolic dysfunction-associated steatohepatitis remains elusive.
Population
Mouse model of MASH and an oleic acid-induced HepG2 cellular model
Comparison
ASPP2 deficiency vs control
Design
Preclinical animal and cell study
Authors
Loading...
May inform MASH therapies; leaves open translation from animal models to human disease.
ASPP2 deficiency promotes MASH progression through ACSL4 upregulation, identifying a potential mechanistic pathway and therapeutic target for MASH.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: